On schedule for completion in Q4 2013, the interim analysis of the trial has preliminarily demonstrated a significant improvement from the baseline in clinical scores for SF-36, NRS-11, and WOMAC osteoarthritis indices, and no serious adverse events have been reported.
http://www.sys-con.com/node/2781752
http://www.sys-con.com/node/2781752
No comments:
Post a Comment